skip to content

Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.